The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy
C Claus, C Ferrara-Koller, C Klein - MAbs, 2023 - Taylor & Francis
The clinical development of 4–1BB agonists for cancer immunotherapy has raised
substantial interest during the past decade. The first generation of 4–1BB agonistic …
substantial interest during the past decade. The first generation of 4–1BB agonistic …
CD137 stimulation enhances cetuximab-induced natural killer: dendritic cell priming of antitumor T-cell immunity in patients with head and neck cancer
Purpose: Cetuximab, an EGFR-specific antibody (mAb), modestly improves clinical outcome
in patients with head and neck cancer (HNC). Cetuximab mediates natural killer (NK) cell …
in patients with head and neck cancer (HNC). Cetuximab mediates natural killer (NK) cell …
[HTML][HTML] A distinct transcriptional program in human CAR T cells bearing the 4-1BB signaling domain revealed by scRNA-seq
AC Boroughs, RC Larson, ND Marjanovic, K Gosik… - Molecular Therapy, 2020 - cell.com
T cells engineered to express chimeric antigen receptors (CARs) targeting CD19 have
produced impressive outcomes for the treatment of B cell malignancies, but different …
produced impressive outcomes for the treatment of B cell malignancies, but different …
Reconstructing the immune system with lentiviral vectors
H Olbrich, C Slabik, R Stripecke - Virus Genes, 2017 - Springer
Lentiviral vectors (LVs) developed in the past two decades for research and pre-clinical
purposes have entered clinical trials with remarkable safety and efficacy performances …
purposes have entered clinical trials with remarkable safety and efficacy performances …
Local treatment of a pediatric osteosarcoma model with a 4-1BBL armed oncolytic adenovirus results in an antitumor effect and leads to immune memory
N Martinez-Velez, V Laspidea, M Zalacain… - Molecular cancer …, 2022 - AACR
Osteosarcoma is an aggressive bone tumor occurring primarily in pediatric patients. Despite
years of intensive research, the outcomes of patients with metastatic disease or those who …
years of intensive research, the outcomes of patients with metastatic disease or those who …
An adenoviral cancer vaccine co-encoding a tumor associated antigen together with secreted 4-1BBL leads to delayed tumor progression
E Ragonnaud, AMC Andersson, AE Pedersen… - Vaccine, 2016 - Elsevier
Previous studies have shown promising results when using an agonistic anti-4-1BB
antibody treatment against established tumors. While this is promising, this type of treatment …
antibody treatment against established tumors. While this is promising, this type of treatment …
Constitutive interaction between 4-1BB and 4-1BBL on murine LPS-activated bone marrow dendritic cells masks detection of 4-1BBL by TKS-1 but not 19H3 antibody
AN Mbanwi, GHY Lin, KC Wang, TH Watts - Journal of Immunological …, 2017 - Elsevier
1BB is a TNFR family member associated with NF-κB mediated survival signaling. 4-1BB is
widely expressed on activated cells of the immune system, including activated T cells, NK …
widely expressed on activated cells of the immune system, including activated T cells, NK …
Kinetics and timing of IL-12 production by dendritic cells for Th1 polarization\(in\)\(vivo\)
DE Ashour - 2020 - opus.bibliothek.uni-wuerzburg.de
Dendritic cell (DC) based vaccines rely on the quality of DC maturation to induce antigen
presentation, co-stimulation, lymph node migration and the release of heterodimeric IL …
presentation, co-stimulation, lymph node migration and the release of heterodimeric IL …